anorectic

L-Cysteine hydrochloride hydrate (L-Cysteine hydrochloride monohydrate) is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), taurine and glutathione. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans.

Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.

Neosolaniol, a type A trichothecene mycotoxin produced by Fusarium species, strongly induces an anorectic (loss of appetite) response.

Norfenfluramine hydrochloride ((±)-Norfenfluramine hydrochloride) is the primary metabolite of Fenfluramine, resulting from its N-dealkylation. It serves as a potent anorectic agent and can modulate serotonin neurotransmission. In addition, Norfenfluramine hydrochloride exhibits sedative effects following acute administration.

Cloforex (Frenapyl) is an orally active anorectic amphetamine derivative and a prodrug of chlorphentermine. It is utilized to induce the accumulation of foam cells in rats.

SKF-77,434 is a drug that acts as a selective dopamine D1 receptor partial agonist. It also has stimulant and anorectic effects.

Fpl 14294 is a novel CCK-8 agonist with effective intranasal anorectic activity in the rat.

HMR-1426 is gastric emptying inhibitor. HMR1426 shows an anorectic potential in rats and decreased body weight and fat mass. This was achieved solely by reducing food intake without influencing overall energy expenditure or behavior.

SNAP-7941 is a selective antagonist of the melanin concentrating hormone receptor MCH1 with promising anxiolytic, antidepressant and anorectic effects in initial animal studies.

VER-3323 is a selective agonist for the 5-HT2B and 5-HT2C serotonin receptor with potent anorectic effects in animal studies.

Peptide YY (PYY) is a 36-amino acid peptide and anorectic gut hormone agonist for the neuropeptide Y receptors Y1, Y2, Y5, and Y6 with EC50 values of 0.7, 0.58, 1, and 0.8 nM, respectively, for supression of forskolin-induced cAMP accumulation. PYY is cleaved in vivo to PYY (3-36) . Release of PYY occurs postprandially in proportion to calorie intake from intestinal enteroendocrine L cells, indicating it may be a satiety signal. In humans, PYY inhibits food intake and gastrointestinal transit in both lean and obese subjects.

CTX-1211 is a selective and orally active melanocortin 4 receptor (MC4R) agonist with an EC50 of 0.38 nM. It enhances the effects of liraglutide in suppressing food intake and promoting weight loss, supporting anorectic and weight-reducing activities. CTX-1211 is primarily employed in research related to obesity and other metabolic disorders.

NNC0165-1273(TFA) is the trifluoroacetate salt form of NNC0165-1273. It is an analog of the gut hormone peptide YY (PYY3-36). The compound shows a significantly higher affinity for the Y2 receptor compared to Y1, Y4, and Y5 receptors. NNC0165-1273 exhibits potent anorectic effects, significantly reducing nocturnal and ghrelin-induced food intake by promoting early satiety. It also inhibits cFos expression in NPY/AgRP neurons induced by ghrelin. NNC0165-1273 can be utilized in research focused on anti-obesity therapies.

N-Palmitoyl phosphatidylethanolamine (Tripelargonin) is an endogenous lipid anorectic hormone that significantly reduces food intake in a dose-dependent manner.